Opinion
Video
Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
Author(s):
The colorectal cancer experts offer insights on a patient case and investigate the obstacles faced by patients with metastatic colorectal cancer requiring third-line or later therapy.
EP: 1.Overview of Molecular Testing and Barriers in mCRC
EP: 2.Clinical Considerations for 2L Treatment Sequencing in mCRC
EP: 3.Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
EP: 4.Exploring Toxicities for Second Line Treatments in mCRC
Now Viewing
EP: 5.Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
EP: 6.Factors Driving 3L Therapeutic Selection for mCRC
EP: 7.Exploring Data Outcomes From the SUNLIGHT Trial
EP: 8.Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies
EP: 9.Examining the Evolving 3L Treatment Landscape for mCRC
EP: 10.Additional Key Takeaways of ASCO 2024 Data in mCR
EP: 11.Future Outlooks in the Treatment of Metastatic Colorectal Cancer
- Dr Marshall to Panel: Briefly provide comments and perspectives on this patient case.
- Dr Marshall to Dr Ciombor: What present challenges exist for patients with mCRC requiring 3L+ therapy?
- With evolving data and latest approvals, have we gotten closer to addressing those challenges and if so, how?
Related Videos
Related Content
%20(2)%201-Recovered-Recovered.jpg?fit=crop&auto=format)
